DBV Technologies SA - American (DBV1) Price & Analysis

1 Followers

DBV1 Stock Chart & Stats

€11.80

-€0.20(-1.69%)

At close: Jul 29 4:00 PM EDT

€11.80

-€0.20(-1.69%)

Day’s Range― - ―

52-Week Range€7.25 - €24.40

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€702.17M

Enterprise Value€1.09K

Total Cash (Recent Filing)€174.90M

Total Debt (Recent Filing)€21.00M

Price to Earnings (P/E)―

Beta-0.42

Next Earnings

Oct 28, 2026

EPS Estimate

-0.12

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.98

Shares Outstanding59,217,140

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-0.27

Price to Book (P/B)9.81

Price to Sales (P/S)0.00

P/FCF Ratio-13.67

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€41.98

Price Target Upside255.79% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-0.84

Revenue Forecast (FY)€3.87M

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthThe company’s low debt relative to equity and sizable assets provide a durable multi‑quarter cushion against operating losses. That balance sheet flexibility reduces near‑term solvency risk, giving management runway to complete regulatory work and execute commercialization planning if approval is achieved.

Regulatory Engagement De‑riskingIterative, collaborative FDA engagement that reportedly did not require new efficacy data and instead focused on organizing existing CMC and biostatistical materials materially reduces regulatory ambiguity. This clarifies the path to a BLA submission and lowers a key structural approval risk for commercialization.

Differentiated EPIT Platform & Launch PrepViaskin’s epicutaneous immunotherapy patch is a differentiated, potentially multi‑allergen platform addressing food allergies. Management’s deliberate investments in launch readiness signal scalable go‑to‑market preparation, which could convert clinical success into enduring commercial capabilities if regulatory approval is secured.

Bears Say

No Revenue & Large LossesThe company generated no material revenue over the trailing twelve months while net losses widened materially, meaning operations lack internal cash inflows. Persistent large losses erode shareholder equity over time and create structural dependence on external capital to sustain R&D and commercialization efforts.

Accelerating Cash Burn & Financing RiskOperating and free cash flow have deteriorated sharply, indicating accelerating cash burn. Maintaining clinical programs and planned launch investments will require material financing, increasing dilution and constraining strategic flexibility; access to capital is a recurring structural risk for execution.

Clinical‑stage Revenue Visibility & Timing RiskAs a clinical‑stage biotech with no commercial track record, revenue and profitability depend on regulatory approval and successful market uptake. Historical revenue lapses and extended timelines create persistent timing and execution risk that can delay or reduce long‑term returns even if approval is eventually obtained.

DBV Technologies SA - American News

Fourteen new option listings and one option delisting on July 22nd

New option listings for July 22nd include Tradr 2X Short AAOI Daily ETF (AAOZ), Alpha Cognition Inc (ACOG),...

8d ago

ACOG

ARTV

DBV Technologies announces $150M at-the-market offering

DBV Technologies (DBVT) announced that it has filed a new automatically effective shelf registration statement with the SEC,...

13d ago

DBVT

DBV Technologies reports Q2 EPS (12c), consensus (9c)

“2026 is an important year for DBV as we continue to prepare to become a commercial company, if...

14d ago

DBVT

DBV Technologies pushout adds ‘timing risk, not data risk,’ says H.C. Wainwright

H.C. Wainwright reiterates the firm’s Buy rating and our $40 price target on DBV Technologies (DBVT) after the...

30d ago

DBVT

Cantor stays bullish on DBV despite one month filing delay

Cantor Fitzgerald analyst Kristen Kluska keeps an Overweight rating on DBV Technologies (DBVT) with a $48 price target...

30d ago

DBVT

DBV Technologies: Buy Rating Reaffirmed with Unchanged $46 Price Target as VIASKIN Peanut BLA Timeline and Regulatory Path De‑Risk

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on DBV Technologies SA – American today and set...

30d ago

DBVT

Fein Reiterates Buy on DBV Technologies, Citing Operational BLA Delay and Unchanged $40 Price Target

H.C. Wainwright analyst Andrew Fein has reiterated their bullish stance on DBVT stock, giving a Buy rating today....

30d ago

DBVT

DBV Technologies delays Viaskin BLA submission to Q3, says Citizens

Citizens analyst Jonathan Wolleben keeps a positive view on DBV Technologies (DBVT) despite pushing its BLA submission for...

1M ago

DBVT

DBV Advances VIASKIN Peanut Patch Toward FDA Submission

An announcement from DBV Technologies SA – American ( ($DBVT) ) is now available. On June 29, 2026,...

1M ago

DBVT

DBV Technologies provides Viaskin Peanut Patch BLA submission update

DBV Technologies (DBVT) provided an update on the biologics license application, or BLA, submission seeking marketing approval of...

1M ago

DBVT

DBV Technologies Shareholders Approve Governance and Capital Measures

DBV Technologies SA – American ( ($DBVT) ) has shared an update. On June 3, 2026, DBV Technologies...

2M ago

DBVT

DBV Technologies Maintained at Buy as Commercialization Prospects Grow; $40 Price Target Reaffirmed

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on DBV Technologies SA...

3M ago

DBVT

DBV Technologies price target raised to $55 from $47 at Citizens

Citizens raised the firm’s price target on DBV Technologies (DBVT) to $55 from $47 and keeps an Outperform...

3M ago

DBVT

DBV Technologies reports Q1 EPS (11c), consensus (12c)

“The entire DBV team has been operating with exceptional focus and rigor as we progress towards significant milestones...

3M ago

DBVT

DBV1 FAQ

What was DBV Technologies SA - American’s price range in the past 12 months?

DBV Technologies SA - American lowest stock price was €7.25 and its highest was €24.40 in the past 12 months.

What is DBV Technologies SA - American’s market cap?

DBV Technologies SA - American’s market cap is €702.17M.

When is DBV Technologies SA - American’s upcoming earnings report date?

DBV Technologies SA - American’s upcoming earnings report date is Oct 28, 2026 which is in 90 days.

How were DBV Technologies SA - American’s earnings last quarter?

DBV Technologies SA - American released its earnings results on Jul 16, 2026. The company reported -€0.106 earnings per share for the quarter, missing the consensus estimate of -€0.095 by -€0.011.

Is DBV Technologies SA - American overvalued?

According to Wall Street analysts DBV Technologies SA - American’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does DBV Technologies SA - American pay dividends?

DBV Technologies SA - American does not currently pay dividends.

What is DBV Technologies SA - American’s EPS estimate?

DBV Technologies SA - American’s EPS estimate is -0.12.

How many shares outstanding does DBV Technologies SA - American have?

DBV Technologies SA - American has 59,217,140 shares outstanding.

What happened to DBV Technologies SA - American’s price movement after its last earnings report?

DBV Technologies SA - American reported an EPS of -€0.106 in its last earnings report, missing expectations of -€0.095. Following the earnings report the stock price went down -6.015%.

Which hedge fund is a major shareholder of DBV Technologies SA - American?

Currently, no hedge funds are holding shares in DE:DBV1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

DBV Technologies SA - American Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

55.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

DBV Technologies SA - American

DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.

DBV Technologies SA - American (DBV1) Earnings & Revenues

Historic Earnings Reports

DBV1 Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presents a positive outlook with significant progress in Viaskin Peanut development and financial management. However, regulatory challenges and increased operating expenses pose some concerns. The overall sentiment is cautiously optimistic with a positive tilt due to successful trial milestones and extended cash runway.View all DE:DBV1 earnings summaries

DBV1 Stock 12 Month Forecast

Average Price Target

€41.98

▲(255.79% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","49":"€49","13.75":"€13.75","25.5":"€25.5","37.25":"€37.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48.30659075,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€48.31</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41.98281887,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€41.98</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.132066,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€35.13</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,13.75,25.5,37.25,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.2,16.823583903846153,19.447167807692306,22.07075171153846,24.694335615384613,27.317919519230767,29.94150342307692,32.56508732692308,35.18867123076923,37.812255134615384,40.43583903846154,43.05942294230769,45.683006846153845,{"y":48.30659075,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.2,16.33713991307692,18.474279826153847,20.61141973923077,22.74855965230769,24.885699565384616,27.022839478461538,29.159979391538464,31.297119304615386,33.43425921769231,35.57139913076924,37.70853904384616,39.84567895692308,{"y":41.98281887,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.2,15.810158923076923,17.420317846153846,19.03047676923077,20.640635692307693,22.250794615384613,23.860953538461537,25.47111246153846,27.081271384615384,28.691430307692308,30.30158923076923,31.911748153846155,33.52190707692308,{"y":35.132066,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.24,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.3,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.1,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.2,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.3,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.9,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.9,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.3,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.2,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >